Revolution Medicines, Inc. (RVMD) |
|
20.92 -0.19 (-0.9%)
|
03-24 16:00 |
|
Open: |
21.02 |
Pre. Close: |
21.11 |
|
High:
|
21.06 |
Low:
|
20.27 |
|
Volume:
|
1,117,357 |
Market Cap:
|
2,221(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:29:29 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 29.1 One year: 32.86 |
| Support: |
Support1: 19.7 Support2: 16.39 |
| Resistance: |
Resistance1: 24.91 Resistance2: 28.13 |
| Pivot: |
22.26  |
| Moving Average: |
MA(5): 21.21 MA(20): 23.01
MA(100): 23.78  MA(250): 21.82 |
| MACD: |
MACD(12,26): -1.1 Signal(9): -1 |
| Stochastic oscillator: |
%K(14,3): 20.2 %D(3): 21 |
| RSI: |
RSI(14): 37.5 |
| 52-week: |
High: 31.37 Low: 14.07 |
| Average Vol(K): |
3-Month: 1,269 (K) 10-Days: 1,342 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ RVMD ] has closed above bottom band by 23.5%. Bollinger Bands are 3.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
21.09 - 21.19 |
21.19 - 21.29 |
|
Low:
|
19.97 - 20.1 |
20.1 - 20.22 |
|
Close:
|
20.68 - 20.89 |
20.89 - 21.09 |
|
Company Description |
|
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. |
Headline News |
Fri, 24 Mar 2023
Revolution Medicines, Inc. (NASDAQ:RVMD) Receives Average ... - MarketBeat
Mon, 13 Mar 2023
$140M Bet On Southwest Gas? Check Out These 4 Stocks Insiders ... - Investing.com UK
Sun, 12 Mar 2023
Hsbc Holdings PLC Invests $204000 in Revolution Medicines, Inc ... - MarketBeat
Sat, 11 Mar 2023
Revolution Medicines, Inc. (NASDAQ:RVMD) Q4 2022 Earnings Call Transcript - Yahoo Finance
Wed, 08 Mar 2023
Revolution Medicines, Inc. (NASDAQ:RVMD) Stake Cut by Polar ... - MarketBeat
Tue, 28 Feb 2023
Dentsply Sirona, Chico's FAS, Kontoor Brands And Other Big Stocks ... - Investing.com UK
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
89 (M) |
| Shares Float |
72 (M) |
|
% Held by Insiders
|
1.4 (%) |
|
% Held by Institutions
|
106.1 (%) |
|
Shares Short
|
7,170 (K) |
|
Shares Short P.Month
|
8,130 (K) |
Stock Financials |
|
EPS
|
-2.39 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
8.65 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-845.5 |
|
Return on Assets (ttm)
|
-20 |
|
Return on Equity (ttm)
|
-37.2 |
|
Qtrly Rev. Growth
|
204.8 |
|
Gross Profit (p.s.)
|
-1.78 |
|
Sales Per Share
|
0.33 |
|
EBITDA (p.s.)
|
-2.77 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-202 (M) |
|
Levered Free Cash Flow
|
-113 (M) |
Stock Valuations |
|
PE Ratio
|
-8.79 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
2.41 |
|
Price to Sales
|
62.94 |
|
Price to Cash Flow
|
-9.21 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
